title: Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.
abstract: OBJECTIVE
  Prospective pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 allele can significantly reduce the number of cases of abacavir-related hypersensitivity among HIV-infected patients treated with this drug. The aim of this study was to establish the frequency of the HLA B*5701 variant in HIV-infected Poles.
  
  
  METHODS
  The sequence-specific primer (SSP) test was used to assess the feasibility of the introduction of such testing in clinical practice. For this purpose, 234 randomly selected HIV-positive patients were screened using a low-resolution SSP assay, with HLA B*5701-positive results confirmed using a high-resolution test.
  
  
  CONCLUSIONS
  The HLA B*5701 variant was found in 11 of 234 subjects (4.7%). Testing with the selected method proved quick and reliable.
authors.affiliation: Department of Infectious Diseases and Hepatology, Pomeranian Medical University, Szczecin, Poland. mparczewski@yahoo.co.uk
authors.forename: M
authors.initials: M
authors.lastname: Parczewski
authors.forename: M
authors.initials: M
authors.lastname: Leszczyszyn-Pynka
authors.forename: A
authors.initials: A
authors.lastname: Wnuk
authors.forename: A
authors.initials: A
authors.lastname: Urbañska
authors.forename: K
authors.initials: K
authors.lastname: Fuksiñska
authors.forename: D
authors.initials: D
authors.lastname: Bander
authors.forename: A
authors.initials: A
authors.lastname: Boroñ-Kaczmarska
mesh_terms: D000328:Adult; D000483:Alleles; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000235:genetics*; D005240:Feasibility Studies; D005260:Female; D005787:Gene Frequency; D005820:Genetic Testing; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D015235:HLA-B Antigens / Q000032:analysis / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011044:Poland; D016133:Polymerase Chain Reaction / Q000379:methods; D011237:Predictive Value of Tests; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012882:Skin Tests; D000099227:Abacavir
chemical_list: D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C484830:HLA-B*57:01 antigen